Bernard Schmidt

Study Coordinator for external studies (CRO-based) with focus on identification and evaluation of new development candidates for selected veterinary non-infectious disease indications for local and systemic toleration, oral acceptance, pharmacokinetics, and efficacy in target animals. Report to Head, Global Drug Discovery Animal Health - Discovery Pharmaceutical Specialties, no direct reports

Identification and evaluation of early development candidates for selected veterinary non-infectious disease indications (cardiovascular, renal,and inflammatory disease, pain, cancer, obesity) for local and systemic toleration, oral acceptance, and efficacy vs pharmacokinetics (PK/PD) in target animals. Report to Head, R&D Non-Infectious Diseases, two direct reports

Head of Laboratory, Safety and general pharmacological assessment of development candidates in rodents. Report to head, Clinical Pharmacology and Safety Studies, four direct reports

Head of Laboratory, screening and preclinical in vitro/in vivo characterization of drug development candidates for human central nervous system indications (depression, anxiety, schizophrenia, Alzheimer's Disease, cognitive impairment, stroke). Report to respective Heads, Biochemical and Behavioral Pharmacology (various reorganizations), two to ten direct reports (average four)

Biochemical-pharmacological characterization of novel receptor-coupled neutrotransmission pathways in primary cultures of neuronal cells. Report to team head, no direct reports

Biochemical-pharmacological characterization of the mode of action of novel antidepressants in rats. Report to team head, no direct reports

Molecular Mode of Action CNS-active drugs (here anti-depressive drugs)

Study of Pharmacy